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Summary This study sought to produce monoclonal antibodies (MAbs) which reacted with the MUC2 core
protein. Two MAbs [3A2 (IgGl) and 4F1 (IgM)] were produced by immunising female BALB/c mice with
gel-formed mucin from the LS174T colon cancer cell line followed by a KLH conjugate of a 29 amino acid
synthetic peptide whose sequence was derived from the variable number of tandem repeats (VNTR) region of
a MUC2 cDNA clone.
The MAbs reacted with synthetic MUC2 VNTR peptides but not synthetic MUCI or MUC3 VNTR
peptides, and showed specific reactivity in Western blotting with a high molecular weight protein produced by
the LS174T colon carcinoma cell line. The use of shorter peptides indicated that the minimum peptide epitopes
for these MAbs were different. Mab 3A2 reacted with amino acids 5-19 of the MUC2 VNTR by inhibition
ELISA but not by direct ELISA, while 4FI reacted with this peptide in both assays. Furthermore, 4FI reacted
in direct ELISA when a larger (29 amino acid) MUC2-derived peptide was coated onto the assay plate by
incubating in carbonate buffer or by drying the peptide onto the assay plate, while 3A2 only reacted when this
peptide was coated in carbonate buffer. The different specificity of the MAbs was also illustrated by the
reactivity of 4F1 but not 3A2 with partially deglycosylated cystic fibrosis mucin.
Immunohistochemical analysis with these MAbs revealed a strong reactivity with lung, gastric and colon
tumours relative to normal tissue, with some breast and ovarian tumours also reacting. Both MAbs stained
some normal goblet cells in the perinuclear region but not the mucin droplet or secreted mucin, indicating a
reaction with immature (poorly glycosylated) mucin in the endoplasmic reticulum and/or golgi, but not with
mature (fully glycosylated) mucin. In contrast, tumours showed strong diffuse cytoplasmic staining. 4F1 also
showed weak apical cytoplasmic staining in some goblet cells and stained some tumours which showed no
reactivity with 3A2.
These antibodies should prove useful in the study of MUC2 structure and function, and in the diagnosis of
some tumours.
Mucins are a family of highly glycosylated, high molecular
weight (>200 kDa) glycoproteins present on the surface of
many epithelial cells (Devine & McKenzie, 1992). Increased
expression of mucin epitopes on tumour cells makes them
suitable candidates as tumour markers. Five distinct gene loci
have now been identified in humans, these being renamed
MUC1, MUC2 and MUC3 (Human Gene Mapping Nomen-
clature Committee, 1989) and the names MUC4 and MUC5
have been proposed (Porchet et al., 1991; Aubert et al.,
1991). Each gene codes for a protein containing a variable
number of tandem repeats (VNTR) of 20 (MUC1), 23
(MUC2), 17 (MUC3), 16 (MUC4), and 8 (MUC5) amino
acids, but there is no significant homology between the differ-
ent VNTRs (Gendler et al., 1987; Gum et al., 1989; 1990;
Porchet et al., 1991; Aubert et al., 1991). Many monoclonal
antibodies (MAbs) reacting with the MUC1 VNTR have
been reported (Gendler et al., 1988; Xing et al., 1990; Layton
et al., 1990; Price et al., 1990), and assays incorporating some
of these MAbs have been shown to be particularly useful in
monitoring patients with breast and ovarian cancer (Ward et
al., 1993; Safi et al., 1991; Bhargava et al., 1989). As well as
overexpression of MUC1, altered glycosylation of the VNTR
is responsible for the exposure of these peptide epitopes in
tumours (Gendler et al., 1988; Devine et al., 1990a).
*Despite the success of MUC1 VNTR-reactive MAbs, only
a few MAbs reacting with other VNTR have been reported
(Xing et al., 1992; Price et al., 1991), and the use of these
MAbs for diagnosis and therapy has not been investigated.
The MUC2 mucin is of particular interest since this is a
major component of mucus produced by patients with colon
and lung cancer, as well as those with cystic fibrosis (Gum et
al., 1989; Gerard et al., 1990; Jany et al., 1991). Subse-
quently, by immunising with native colon cancer mucin and a
KLH-synthetic peptide conjugate containing the 23 amino
acid MUC2 VNTR sequence, we have produced anti-MUC2
VNTR MAbs which react with the intact mucin. These
MAbs show a high reactivity with colon, gastric, and lung
tumours by immunohistochemistry, and may prove useful in
the diagnosis and therapy of these tumours.
Materials and methods
Peptides
The peptides used in this study are shown in Table I. The
Ml, M2 and T4N1 peptides were synthesised using an Ap-
plied Biosystems Model 430A automated peptide synthesiser
(Forster City, CA, USA) by Merrifield solid phase synthesis
(Hodges & Merrifield, 1975). Ml corresponds to the 20
amino acid MUC1 repeat plus the first four amino acids of
the next repeat (Gendler et al., 1987); M2 corresponds to the
first 23 amino acid MUC2 repeat plus the first four amino
acids of the next repeat (Gum et al., 1989), with KY added
to the N-terminal for conjugation; T4N1 corresponds to the
N-terminus of mouse CD4 (Clark et al., 1988), and was used
as a control. The M25 19 peptide, synthesised on 'pins'
(Geysen et al., 1984), was donated by Chiron Mimotopes,
Australia, and corresponded to amino acids 5-19 of the first
MUC2 repeat (Gum et al., 1989). The M2N and M2c pep-
tides were produced by cyanogen bromide cleavage of the
M2 peptide (Gross, 1967), and correspond to the N-terminal
and C-terminal portions of the M2 peptide. The M3 peptide
was prepared using the 'tea bag' method (Houghton, 1985),
and represents the 17 amino acid MUC3 repeat plus the first
five amino acids of the next repeat (Gum et al., 1990), with
lysine attached to the N-terminus for conjugation. The pep-
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Table I Peptide inhibition of 3A2 and 4Fl binding
% Inhibition
Peptide Sequence MW (kDa) 3A2 4F1
Ml PDTRPAPGSTAPPAHGVTSAPDTR 2359.1 nd nd
M2 KYPTTTPISTTTMVTPTPTPTGTQTPTTT 3023.7 99 97
M25 19 PISTTTMVTPTPTPT 1512.8 100 98
M2N KYPTTTPISTTTM 1441.7 33 66
M2C VTPTPTPTGTQTPTTT 1600.8 90 93
M3 KSHSTPSFTSSITTTETTSHSTP 2422.6 5 9
T4N1 KTLVLGKEQESAELPCECY 2158.6 0 0
and, not done.
tides were purified by reversed-phase HPLC on a Deltapak-
C18 column (Nihon Waters Ltd, Tokyo, Japan), with a
gradient of acetonitrile in 0.1% TFA, and the identity of
each was confirmed by N-terminal sequencing and mass spec-
troscopy. The M2 peptide was conjugated to keyhole limpet
hemocyanin (KLH) using glutaraldehyde (Zegers et al.,
1990).
Mucins
The LS174T and HT29-SB colon cancer cell lines have been
shown to secrete significant quantities of mucin (Devine et
al., 1991, 1992). Much of the LS174T and HT29-SB mucin is
secreted into the culture media as a viscoelastic gel, which
was harvested by filtration on double thickness lens tissue,
and washed twice on the tissue with water. Cystic fibrosis
(CF) mucin, donated by Dr G. Sachdev, was purified and
deglycosylated with trifluoromethane sulphonic acid (TFM-
SA) (Desai et al., 1991). Human milk fat globule membranes
(HMFGM) were used as a source of MUCI mucin (Devine
et al., 1990b).
Production ofmonoclonal antibodies
BALB/c female mice (8 weeks old) were injected by s.c. and
i.m. routes with LS174T mucin emulsified in Freund's Com-
plete Adjuvant. A second injection was given 6 weeks later,
except the mucin was emulsified in Freund's Incomplete
Adjuvant (FIA) and injected by i.p. and i.m. routes. After a
further 6 weeks, the mouse was injected i.p. and i.m. with
M2-KLH conjugate in FIA. Four weeks later, M2-KLH was
given i.v. in PBS and i.p. in FIA, and the i.p. injection was
repeated for the next 3 days, as this protocol had been shown
to give greater success in the production of anti-peptide
MAbs (Schibier et al., 1988). The spleen cells were fused with
NS1 cells the next day.
Hybridomas were screened by ELISA on LS174T mucin,
M2 and T4N1 peptides (Layton et al., 1990). Positive clones
were then checked by ELISA on Ml, and by immunoblotting
on LS174T and HT29-SB mucins (Devine & Birrell, 1992).
Those showing specificity for LS174T and M2 were cloned
by limiting dilution. The subclass of MAbs was determined
by dual-determinant ELISA using subclass-specific antibodies
to capture MAbs and anti-mouse Ig-peroxidase (Silenus,
Australia) to detect bound MAb.
ELISA
All assays were performed in duplicate, with the percentage
coefficient of variation of duplicates being < 10% in all
cases. Mabs BC2 (IgGI), BC3 (IgM), 401/21 (IgGI), and
FMI (IgM) were used as control antibodies (Xing et al.,
1989; Skerritt & Hill, 1990; Devine et al., 1990b). BC2 and
BC3 react with the minimum epitope APDTR on the MUCI
VNTR (Xing et al., 1990), 401/21 reacts with wheat protein
gliadins (Skerritt & Hill, 1990), while the specificity of FM1
has not been determined.
Solid-Phase ELISA Peptides (2.5jig dry weight ml-') or
mucins (40 tLg dry weight LS174T mucin ml-' or 5jg dry
weight CF mucin ml-') were coated onto a Falcon flexible
assay plate (Becton Dickinson, USA) by incubating overnight
at 4'C in 0.1 M carbonate buffer pH 9.6, or by drying onto
the plate in vacuo at 30°C. Plates were blocked for 2 h at
room temperature (RT) with Blocking Reagent (Boehringer-
Mannheim, IN, USA, cat. no. 1142372), and incubated over-
night with MAb in phosphate buffered saline containing
0.05% Tween-20 (PBS-Tween). Bound MAb was detected
using anti-mouse Ig-peroxidase (Silenus, Australia) and
ABTS substrate (Devine et al., 1990b). Plates were washed
three times with PBS-Tween between each incubation, and
checkerboard titrations of antigen and MAb were performed.
Blocked plates containing no antigen were also tested to
determine any non-specific binding.
Inhibition ELISA Optimal concentrations of antigens and
MAbs were determined by checkerboard ELISA, and inhibi-
tion ELISA was performed (Layton et al., 1990). Briefly,
MAbs at twice the required concentration (3A2 ascites
2000-', 4F1 ascites 5000-1) were incubated for 3 h at RT
with an equal volume of peptide (64 fM) in PBS-Tween. 'No
inhibition' (MAb plus PBS-Tween) and 'total inhibition'
(PBS-Tween, no MAb) incubations were also performed.
Subsequently, 50,il was transferred to a peptide-coated plate
(1.25 gLg dry weight ml-' for 3A2, 0.125ytg dry weight ml'
for 4F1) and the assay was completed as above. Inhibition
was calculated as described (Layton et al., 1987).
Cell staining
The reactivity of MAbs was tested on a panel of colon
carcinoma cell lines (LS174T, LIM1899, LIM2099, LIM2358,
LIM2405, LIM2412, LIM2463, LIM2537) (Whitehead et al.,
1985, 1992). Adherent cell lines were grown to confluence,
scraped and a pellet of cells was embedded in OCT freezing
mixture (Miles Laboratories, USA) and stored at - 20'C
until cut. Cells grown in suspension were harvested, pelleted
and processed similarly. The sections were fixed at room
temperature in cold acetone for 10 min and air dried before
staining with MAbs using the standard two-layer immuno-
peroxidase technique. Mabs (hybridoma supernatant at 10-')
were detected using rabbit anti-mouse peroxidase (DAKO,
USA) followed by incubation with DAB substrate.
Western blotting
Proteins were separated on 3-15% SDS-polyacrylamide gels,
and Western blotting was performed as described, with pre-
stained high molecular weight markers (BioRad, MA, USA)
run alongside the samples (Devine et al., 1990a). Gel-formed
mucin was dissolved in Tris buffer pH 6.8 containing 3%
SDS and 20% glycerol. In some cases, 5% 2-mercapto-
ethanol was also included to reduce disulphide linkages. The
samples were boiled for 10 min before performing electro-
phoresis.
Immunohistochemistry specimens andanalysis
All tissues were selected retrospectively from the files of the
Departments of Pathology at the Royal Brisbane and Prince
Charles Hospitals. All tissue was formalin fixed and embed-
ded in paraffin. A single block, which was considered to be1184 P.L. DEVINE et al.
representative of the tumour was selected; and S ,tm sections
were mounted on glass slides for immunohistochemical ana-
lysis. Tissue tested comprised; ten cases each of colonic,
gastric, and lung cancers (five adenocarcinomas, two squa-
mous cell carcinomas, one adenosquamous, one epidermoid)
and 11 breast cancers; seven cases of non-mucinous and
seven cases of mucinous cystadenocarcinomas of the ovary;
and five cases of benign ovarian tumours. Stained sections
were analysed by a single investigator (MAM) and the anti-
gen was recorded as being either absent or present in less
than 25%, 25-50%, 50-75%, or more than 75% of tumour
cells. The cellular localisation of antigens was recorded as
being membranous, cytoplasmic, or both (membrane staining
was defined as being luminal alone or along the entire mem-
brane). Intensity of staining was scored on a four point scale.
Non-malignant colonic, gastric, lung and breast tissue, ob-
tained from non-involved resection margins were also asse-
ssed and expression of the antigens described. Mesothelioma
cells were isolated from pleural fluid and treated as above,
except fixation was done in methacarn.
Immunohistochemistry techniques
Immunohistochemistry was performed (McGuckin et al.,
1990) with MAb ascites at 1000-1. Sections were stained with
3A2, 4F1, and negative control MAb FM1.
peptide was inhibited by M2, M25 ,9, M2N, and M2C pep-
tides, but not the M3 or T4N1 peptides (Ml not tested).
However, the M2, M25-,9 and M2C peptides showed greater
inhibition of MAb binding than the M2N peptide, particular-
ly with 3A2. It is also of interest to note that MAb 4F1 also
reacted with the M25 19 peptide by solid-phase ELISA while
MAb 3A2 showed no reactivity with this peptide in this assay
system. Furthermore, when peptides were dried in vacuo on
to the microtitre plate, 3A2 showed no reactivity with M2
while 4F1 reacted strongly (not shown).
Reactivity ofantibodies with cysticfibrosis (CF) mucin
The reactivity of MAbs with native and partially deglyco-
sylated cystic fibrosis mucin was determined by solid-phase
ELISA. Mab 3A2 showed very weak reactivity with either
mucin (not shown), while 4F1 reacted weakly with native
mucin and showed strong reactivity with partially degly-
cosylated CF mucin produced by TFMSA treatment (Figure
2). Control MAbs 401/21 and FM1 were negative.
Reaction of3A2 and 4Ff with human tumour cell lines
A panel of human colon cancer cell lines was tested in the
cell ELISA with MAbs 3A2 and 4F1 (Table II). Staining
ranged from 0-100% of cells, with cytoplasmic staining in
all cases. The LIM2463 cell line showed the greatest expres-
sion of the peptide epitopes detected by 3A2 and 4F1 (100%
Results
Production ofMUC2 reactive monoclonal antibodies
Monoclonal antibodies 3A2 (IgGj) and 4F1 (IgM) were
chosen after the fusion, as these reacted with LS174T mucin
and the M2 peptide, but not HMFGM or the M1, M2 and
T4N1 peptides (not shown). Control MAbs 401/21 and FMl
were negative in all cases, while MAbs BC2 and BC3 reacted
with HMFGM and the Ml peptide but not with other
antigens (not shown). After these hybridomas were cloned
and produced as ascites in mice, checkerboard titration
showed that the reactivity of both MAbs with M2 peptide
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Figure 1 Reactivity of MAbs 3A2 (open symbols) and 4F1
(closed symbols) with the M2 (O *) and T4N1 (A A) peptides
and LS174T gel-formed mucin (0 *) by direct ELISA. Peptide
was coated at 2.5 pg dry weight ml- in 0.1 M carbonate pH 9.6,
while mucin was coated at 40 sg dry weight ml-' by incubation
in vacuo at 30C as described in the Materials and methods
section. The plates were read after a 5 min (M2 and T4N1) or
15 min (mucin) incubation with substrate. Background values
have been subtracted. Peptides Ml, M3 and T4N1 were non-
reactive in this assay (not shown).
Ascites dilution
Figure 2 Reactivity of MAb 4F1 with native (0) and partially
deglycosylated (A) cystic fibrosis mucin by direct ELISA. Mucin
was coated at 5 Lg dry weight ml-' by incubation in vacuo at
30C as described in the Materials and methods. Mab 3A2
showed weak reactivity with both mucins, while 401/21 and FMI
were negative (not shown).
Table II Reactivity of mabs 3A2 and 4F1 with human colonic
tumour cell lines
Cell line 3A2 4Ff
LIM1215 Weak cytoplasmic Granular cytoplasmic
stain (20% cells) stain (<5% cells)
LIM1899 Granular cytoplasmic Granular cytoplasmic
stain (10-25% (25% cells)
cells)
LIM2099 Weak cytoplasmic Negative




LIM2412 Strong cytoplasmic Negative
stain (5% cells)
LIM2463 Strong cytoplasmic Granular cytoplasmic
stain (100% cells) stain (100% cells)
LIM2537 Negative Weak cytoplasmic
stain (20% cells)
LS174T Weak cytoplasmic Weak cytoplasmic
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of cells reactive), while the LIM1899 cell line also showed
strong reactivity in 25% of cells. The MAbs also reacted with
the LS174T cell line, which was the source of the MUC2
used as immunogen.
Analysis ofmucins by western blotting
Gel-formed mucin from the LS174T colon carcinoma cell line
reacted with MAbs 3A2 and 4F1, but not control MAbs
401/21 or FM1 (Figure 3). Both MAbs reacted under reduc-
ing and non-reducing conditions with a single high molecular
weight band of molecular weight greater than 400 kDa.
There was no reaction, however, with gel-formed mucin pro-
duced by the HT29-SB colon carcinoma cell line (not shown).
Reactivity ofantibodies with non-malignant tissue by
immunoperoxidase staining
Both 4F1 and 3A2 antibodies reacted with some epithelial
components of non-malignant colonic, gastric and lung tis-
sue, but not with non-malignant breast epithelium. In normal
colon, 4F1 antigen expression was typified by diffuse cyto-
plasmic staining of the colonic mucosal surface, although
antigen was not detected within goblet cell mucin droplets.
The proportion of positive cells varied between specimens
from 10 to 75% of surface epithelial cells, and staining
decreased deeper in the mucosal crypts. Occasionally,
stronger granular staining in peri- and supra-nuclear regions
of goblet cells was observed (Figure 4a). In contrast, 3A2
expression was mainly restricted to such granular staining in
the basal region of goblet cells, although some specimens
showed a small proportion of cells with diffuse cytoplasmic
staining similar to that found for 4F1. In most specimens,
less than 10% of goblet cells were positive with most staining
in the outer cells of crypts (Figure 4b,c). In normal stomach,
4F1 staining revealed diffuse cytoplasmic antigen in pyloric
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Figure 3 Reactivity of MAbs a, 4F1, b, 3A2, c, FMI and d,
401/21 with non-reduced LS174T mucin by Western blotting.
HT29-SB mucin was negative in all cases (not shown). The
positions of BioRad prestained high molecular weight markers
are shown. The top of the running gel is shown by a black line.
glands and more granular cytoplasmic staining in cells of the
surface epithelium. The proportion of cells positive varied
widely between specimens from no staining to about 25% of
cells positive. 3A2 expression was less but similar where
present, although in some specimens surface epithelial cells
showed strong granular cytoplasmic staining confined to the
basal region of the cell. In lung tissue, neither 4F1 or 3A2
stained alveoli but some weak staining was observed with
both antibodies in bronchioles and mucinous glands. In
bronchial epithelium diffuse cytoplasmic staining was found
in the apical region of some columnar cells but staining was
not observed in mucin droplets of goblet cells. In mucinous
glands diffuse cytoplasmic staining was found in a small
proportion of cells using 4F1 but not 3A2. Only one of five
benign ovarian tumours was positive for 4F1, and none for
3A2. The 4F1 positive tumour was a benign mucinous
tumour that showed cytoplasmic staining in almost all cells.
Reactivity ofantibodies with malignant tumours by
immunoperoxidase staining
Expression of the epitopes defined by 4F1 and 3A2 in malig-
nant tumours are summarised in Table III, with represen-
tative sections shown in Figure 4. Expression of each antigen
was variable within all tumour types. All colon carcinomas
were positive for both 4F1 and 3A2 with the exception of
one well differentiated carcinoma of the sigmoid colon.
Although typically less cells were positive for 3A2 than for
4F1, 3A2 often revealed strong granular cytoplasmic staining
compared with the diffuse cytoplasmic staining characteristic
of4F1. Granular cytoplasmic staining was not restricted to a
subcellular compartment as was the case in non-malignant
epithelium. Neither membrane or extracellular antigen was
detected by either antibody. Most gastric carcinomas showed
cytoplasmic 4F1 expression in a majority of tumour cells.
Less tumours were positive for 3A2, and where the antigen
was present a lower proportion of tumour cells were positive
than for 4F1. Strong granular staining was again more
typical of 3A2 than 4F1. All lung cancers were positive for
the 4F1 antigen with the exception of the one neuroendocrine
tumour. Six of ten lung tumours showed 3A2 expression, and
where the antigen was present a lower proportion of tumour
cells were positive. Expression of both antigens was usually
of weak to moderate intensity with diffuse cytoplasmic stain-
ing, although in some tumours foci of coexistant strong
granular cytoplasmic staining were present. The 4F1 epitope
was found in both mucinous and non-mucinous ovarian
carcinomas, although the proportion of cells positive was
greater in mucinous tumours. Staining of ovarian tumours
was also restricted to the cytoplasm. Only half of the ovarian
tumours were positive for 3A2 and where present this epitope
was typically restricted to a small proportion of tumour cells.
The 4F1 and 3A2 epitopes were found in approximately half
of the cases of invasive breast carcinoma. Staining was cyto-
plasmic except for weak coexistent membrane staining in two
of the cases. Ductal carcinoma in situ was present in two of
the positive cases, and in both cases, these lesions expressed
the 4F1 and 3A2 epitopes, although with a different staining
pattern to the adjacent invasive tumour. The antibodies also
reacted with 5/6 (4F1) and 3/6 (3A2) mesotheliomas.
Discussion
The isolation of cDNA clones coding for the protein core of
MUC2 mucin (Gum et al., 1990) has enabled us to use a
synthetic peptide as immunogen for the production of anti-
MUC2 core peptide-reactive monoclonal antibodies. Two
MAbs were produced, 3A2 (IgGl) and 4F1 (IgM), and these
reacted specifically with synthetic MUC2-derived peptides,
colon carcinoma cell lines, and paraffin embedded sections of
various cancer tissue. However, subtle differences in the reac-
tivity of the two MAbs were observed.
Both MAbs reacted with MUC2 peptide but not MUC1 or
MUC3 peptides, and showed specific reactivity with a high1186 P.L. DEVINE et al.
a
c d
Figure 4 Tumour and non-malignant tissue sections stained wtih 3A2 and 4F1; peroxidase diaminobenzidine, haematoxylin. a,
Moderately differentiated adenocarcinoma of the colon and adjacent uninvolved colonic mucosa, 4F1. Note the diffuse staining in
tumour cells (arrow) and perinuclear staining in normal cells. b, As with a, 3A2. Note only isolated positive tumour cells (arrow)
and perinuclear staining in normal mucosal cells. c, Colonic mucosal surface of a normal colonic mucosal crypt, 3A2. Note strong
perinuclear staining in some cells (arrow) but lack of reactivity with the mucin droplet. d, Large cell carcinoma of the lung, 4F1.
Note diffuse cytoplasmic staining in tumour cells (arrow). e, Mucinous cystadenocarcinoma of the ovary, 3A2. Note intense
perinuclear staining and lack of reactivity in the mucin droplets. f, Infiltrating ductal carcinoma of the breast, 4F1. Note the strong
cytoplasmic staining of carcinoma cells but the lack of reactivity with adjacent epithelial hyperplasia (arrow). Scale bars:
a,b,f = 100 gm; c,d,e = 40 rim.
molecular weight mucin-like molecule produced by the
LS174T colon carcinoma cell line. It was of interest that
these MAbs showed some reactivity with the shorter MUC2
peptides tested, which represent different regions of the
MUC2 VNTR. All peptides (M25 19, M2N, and M2C) con-
tained the sequence TTT, as well as PT and TP containing
regions, suggesting that these amino acids may be part of the
epitopes for these MAbs. The M3 peptide, which was not
detected by these MAbs, also contains the sequence TTT,
suggesting that TTT is not the minimum epitope. Further-
more, the M2N peptide showed weaker inhibition than the
other peptides, suggesting that the epitope for optimum bind-
ing may lie in the region PTPTPT common to the M5 -9 and
M2c peptides. It is of interest that MAb GL-013, raised
against gastric carcinoma cells, was shown to react with a
TTT-containing minimum epitope on the MUC2 VNTR (Price
b
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Table III Expression of the antigens defined by monoclonal
antibodies 4F1 and 3A2 in malignant tumours of the colon, stomach,
lung, ovary, and breast, and mesotheliomas
Tumour Percentage of tumour cells positivea
type n 0 1-25 25-50 50-75 75-100
4FI
Colon 10 1 2 0 4 3
Stomach 10 1 1 0 2 6
Lung 10 1 1 2 2 4
Ovary muc 7 1 1 1 2 2
non-muc 7 2 2 2 1 0
Breast 11 7 1 1 1 1
Mesothelioma 6 1 0 0 0 5
3A2
Colon 10 1 5 2 1 1
Stomach 10 3 3 2 2 0
Lung 10 4 2 3 0 1
Ovary muc 7 3 2 1 1 0
non-muc 7 4 2 1 0 0
Breast 11 6 2 2 0 1
Mesothelioma 6 3 0 0 1 2
aControl mab FMI was negative on all samples.
et al., 1991), suggesting that 3A2 and 4F1 react with a
different part of the MUC2 VNTR. However, the position of
an epitope in a synthetic peptide has been shown to affect
MAb reactivity (McKenzie & Xing, 1990), and firm con-
clusions regarding the epitopes for these MAbs cannot be
drawn from these experiments. Further experiments with
shorter overlapping peptides are needed to define the
minimum epitopes of these MAbs.
Differences in the fine specificity of MAbs 3A2 and 4F1
were also illustrated by the reactivity of 3A2 with the M25-19
peptide by inhibition ELISA but not direct ELISA, while
4F1 reacted with this peptide in both assay systems. In
addition, the reactivity of 3A2 with the M2 peptide in direct
ELISA was dependent on the method of plate coating. This
may explain the weaker reactivity of 3A2 with LS174T mucin
and CF mucin by direct ELISA. In addition, the consensus
sequence of the MUC2 VNTR from intestine is slightly
different to that of tracheobronchial tissue (Gerard et al.,
1991), so the difference in reactivity with CF mucin may be
due to differences in the minimum epitopes of 3A2 and 4F1.
The observations from immunohistochemical staining of
both normal and malignant tissues are consistent with 4F1
and 3A2 recognising different epitopes on the protein core of
the MUC2 mucin. Cellular distribution of these epitopes in
normal gastro-intestinal and respiratory tissues was similar to
that described for antigens recognised by polyclonal anti-
bodies prepared against deglycosylated LS174T mucin (Yan
et al., 1990) and deglycosylated sputum from a cystic fibrosis
patient (Perini et al., 1989). The perinuclear granular stain-
ing, seen particularly with 3A2, probably represents detection
of the protein core in the endoplasmic reticulum or golgi
apparatus prior to the completion of glycosylation. The lack
of reactivity of both antibodies with mucin droplets of
globlet cells and luminal secretions suggests low reactivity
with the mature mucin in normal cells. The observation that
not all cells of a given type showed equal expression of either
epitope is consistent with the findings of other studies utilis-
ing various antibodies to colonic and/or respiratory mucins
(Yan et al., 1990; Perini et al., 1989; Podolsky et al., 1986;
Finkbeiner & Basbaum, 1988). These findings suggest either
phenotypic or stage dependent maturational differences may
exist in mucin production patterns ofmorphologically similar
cells.
Detection of the 4F1 and 3A2 epitopes in colonic, gastric,
lung, breast, and ovarian cancers demonstrates continued
MUC2 production by at least some carcinomas derived from
these organs. The expression of both epitopes in some malig-
nancies was much greater than their expression by correspond-
ing non-malignant cells. Increased expression in cancers
could reflect either increased production and/or undergly-
cosylation of MUC2. The loss of compartmentalisation of
granular cytoplasmic staining is consistent with the loss of
polarity that occurs following malignant transformation
of epithelial cells. Larger numbers of specimens are required
to fully assess the relative expression in different histological
types. However, it appears the degree of differentiation has
little effect on expression in colon and gastric carcinomas.
MUC2 was expressed in both mucinous and non-mucinous
ovarian carcinomas. Unfortunately, this finding prevents the
use of MUC2 detection for differential diagnosis of gas-
trointestinal and mucinous ovarian pelvic and peritoneal
malignancies. In addition, MUC2 was also expressed by
mesotheliomas, and these MAbs could not be used for the
differential diagnosis of mesothelioma and adenocarcinoma.
The 4F1 and 3A2 epitope expression detected in some cases
of breast carcinoma is consistent with the findings of Yan et
al. (1990) who found a small percentage of cells positive for
antibodies against deglycosylated colon mucin in one of five
breast cancers, and Jany et al. (1991) who demonstrated the
presence of MUC2 RNA in mammary tissue. Although
antigen was not detected in normal breast duct epithelium,
further analysis is required as MUC2 may be expressed by
foetal or lactating breast epithelium.
These antibodies should prove useful in the study of
MUC2 structure and function, and also have potential as
diagnostic and therapeutic agents. The production of second
generation anti-peptide antibodies represents a useful method
of producing anti-tumour reagents, and this technology may
also be applied to the production of MAbs to the other
mucin core proteins.
The authors wish to acknowledge Louise Ramm and Sharma Khan
for technical assistance, and Drs Gordon Wright and A. Firouz-
Abadi for providing pathological material.
References
AUBERT, J.-P., PORCHET, N., CREPIN, M., DUTERQUE-COQUIL-
LAUD, M., VERGNES, G., MAZZUCA, M., DEBUIRE, B., PETI-
TREZ, D. & DEGAND, P. (1991). Evidence for different human
tracheobronchial mucin peptides deduced from nucleotide cDNA
sequences. Am. J. Resp. Cell. Mol. Biol., 5, 178-185.
BHARGAVA, A.K., PETRELLI, N.J., MYERS, M.M., KHAN, S., FITZ-
PATRICK, J., BURKE, P., ANSELMINO, L. & MANDERINO, G.
(1989). A new breast cancer marker (BCM) in monitoring disease
status. J. Tumor Marker Oncol., 4, 373-381.
CLARK, G.J., TOBIAS, G.H., PIETERSZ, G.A., CLASSON, B.J., WALK-
ER, I.D., MCKENZIE, I.F.C. & DEACON, L.J. (1988). Isolation of a
cDNA clone from the murine CD4 antigen. Transplant. Proc., 20,
45-48.
DESAI, V.C., NAZIRUDDIN, B., GRAVES, D.C., DE LA ROCHA, S.R. &
SACHDEV, G.P. (1991). Production and characterisation of mono-
clonal antibodies to purified deglycosylated cystic fibrosis respir-
atory mucin: evidence for the presence of four immunologically
distinct epitopes. Hybridoma, 10, 285-296.
DEVINE, P.L., WARREN, J.A., WARD, B.G., MCKENZIE, I.F.C. &
LAYTON, G.T. (1990a). Glycosylation and the exposure of tumor-
associated epitopes on mucins. J. Tumor Marker Oncol., 5,
11-26.
DEVINE, P.L., WARREN, J.A., CLARK, B.A., LAYTON, G.T., WARD,
B.G., MACDONALD, B., XING, P.-X. & MCKENZIE, I.F.C. (1990b).
The complexity of cancer-associated epitope expression on anti-
gens produced by ovarian tumor cells. J. Tumor Marker Oncol.,
5, 321-339.
DEVINE, P.L., LAYTON, G.T., CLARK, B.A., BIRRELL, G.W., WARD,
B.G., XING, P.-X. & MCKENZIE, I.F.C. (1991). Production of
MUCI and MUC2 mucins by human tumor cell lines. Biochem.
Biophys. Res. Commun., 178, 593-599.
DEVINE, P.L. & BIRRELL, G.W. (1992). A method for screening large
numbers of samples on immunoblots. J. Immunol. Meth., 149,
143-144.
DEVINE, P.L. & MCKENZIE, I.F.C. (1992). Mucins: structure, func-
tion, and association with malignancy. BioEssays, 14, 619-625.1188 P.L. DEVINE et al.
DEVINE, P.L., BIRRELL, G.W., WHITEHEAD, R.H., HARADA, H.,
XING, P.-X. & McKENZIE, I.F.C. (1992). Expression of MUCI
and MUC2 mucins by human tumor cell lines. Tumor Biol., 13,
267-276.
FINKBEINER, W.E. & BASBAUM, C.B. (1988). Monoclonal antibodies
directed against human airway secretions. Localization and char-
acterization of antigens. Am. J. Pathol., 131, 290-297.
GENDLER, S.J., BURCHELL, J.M., DUHIG, T., LAMPORT, D., WHITE,
R., PARKER, M. & TAYLOR-PAPADIMITRIOU, J. (1987). Cloning
of partial cDNA encoding differentiation and tumor-associated
mucin glycoproteins expressed by human mammary epithelium.
Proc. Natl Acad. Sci. USA, 84, 6060-6064.
GENDLER, S., TAYLOR-PAPADIMITRIOU, J., DUHIG, T., ROTH-
BARD, J. & BURCHELL, J.M. (1988). A highly immunogenic
region of a human polymorphic epithelial mucin expressed by
carcinomas is made up of tandem repeats. J. Biol. Chem., 263,
12820-12823.
GERARD, C., EDDY, R.L. & SHOWS, T.B. (1990). The core polypep-
tide of cystic fibrosis tracheal mucin contains a tandem repeat
structure - evidence for a common mucin in airway and gastro-
intestinal tissue. J. Clin. Invest., 86, 1921-1927.
GEYSON, H.M., MELOEN, R.H. & BARTELING, S.J. (1984). Use of
peptide synthesis to probe viral antigens for epitopes to a resolu-
tion of a single amino acid. Proc. Natl Acad. Sci. USA, 81,
3998-4002.
GROSS, E. (1967). The cyanogen bromide reaction. Meth. Enzymol.,
11, 238-255.
GUM, J.R., BYRD, J.C., HICKS, J.W., TORIBARA, N.W., LAMPORT,
D.T.A. & KIM, Y.S. (1989). Molecular cloning of human intestinal
mucus cDNAs. Sequence analysis and evidence for genetic poly-
morphism. J. Biol. Chem., 264, 6480-6487.
GUM, J.R., HICKS, J.W., SWALLOW, D.M., LEGACE, R.L., BYRD, J.C.,
LAMPORT, D.T.A., SIDDIQUI, B. & KIM, Y.S. (1990). Molecular
cloning of cDNAs derived from a novel human intestinal mucin
gene. Biochem. Biophys. Res. Commun., 171, 407-415.
HODGES, R.S. & MERRIFIELD, R.B. (1975). Monitoring a solid phase
peptide synthesis by an automated spectrophotometric picrate
method. Anal. Biochem., 65, 241-272.
HOUGHTON, R.A. (1985). General method for the rapid solid phase
synthesis of large numbers of peptides: specificity of antigen-
antibody interaction at the level of individual amino acids. Proc.
Nati Acad. Sci. USA, 82, 5131-5135.
HUMAN GENE MAPPING NOMENCLATURE COMMITTEE (1989).
Tenth International Workshop on Human Gene Mapping. Cyto-
genet. Cell Genet., 51, 13-66.
JANY, B.H., GALLUP, M.W., YAN, P.-S., GUM, J.R., KIM, Y.S. &
BASBAUM, C.B. (1991). Human bronchus and intestine express
the same mucin gene. J. Clin. Invest., 87, 77-82.
LAYTON, G.T., STANWORTH, D.R. & AMOS, H.E. (1987). The
specificity ofmurine polyclonal and monoclonal antibodies to the
haptenic drug chlorhexidine induced by chlorine-generated chlor-
hexidine protein conjugates. Clin. Exp. Immunol., 69, 157-165.
LAYTON, G.T., DEVINE, P.L., WARREN, J.A., BIRRELL, G., XING,
P.-X., WARD, B.G. & MCKENZIE, I.F.C. (1990). Monoclonal anti-
bodies reactive with the breast carcinoma-associated mucin core
protein repeat sequence peptide also recognise the ovarian car-
cinoma-associated sebaceous gland antigen. Tumor Biol., 11,
274-286.
MCGUCKIN, M.A., OWENS, M., WRIGHT, R.G., MCKENZIE, I.F.C. &
WARD, B.G. (1990). Demonstration of seven tumor-associated
antigens in epithelial ovarian cancer by immunohistochemistry
using monoclonal antibodies. J. Twnor Marker Oncol., 5, 87-94.
MCKENZIE, I.F.C. & XING, P.-X. (1990). Mucins and breast cancer:
recent immunological advances. Cancer Cells, 2, 75-78.
PERINI, J.-M., MARIANNE, T., LAFITTE, J.-J., LAMBLIN, G., ROUS-
SEL, P. & MAZZUCA, M. (1989). Use of antiserum against degly-
cosylated human mucins for cellular localization of their peptide
precursors: antigenic similarities between bronchial and intestinal
mucins. J. Histochem. Cytochem., 37, 869-875.
PODOLSKY, D.K., FOURNIER, D.A. & LYNCH, K.E. (1986). Human
colonic goblet cells. Demontration of distinct subpopulations
defined by mucin-specific monoclonal antibodies. J. Clin. Invest.,
77, 1263-1271.
PORCHET, N., VAN CONG, N., DUFFOSSE, J., AUDIE, J.P., GUYON-
NET-DUPERAT, V., GROSS, M.S., DENIS, C., DEGAND, P.L,
BERNHEIM, A. & AUBERT, J.P. (1991). Molecular cloning and
chromosomal localisation of a novel human tracheo-bronchial
mucin cDNA containing tandemly repeated sequences of 48 base
pairs. Biochem. Biophys. Res. Commun,. 175, 414-422.
PRICE, M.R., PUGH, J.A., HUDECZ, F., GRIFFITHS, W., JACOBS, E.,
SYMONDS, I.M., CLARKE, A.J. & BALDWYN, R.W. (1990). C595 -
a monoclonal antibody against the protein core ofhuman urinary
epithelial mucin commonly expressed in breast carcinomas. Br. J.
Cancer, 61, 681-686.
PRICE, M.R., SEKOWSKI, M., YANG, G.-L., DURRANT, L.G., ROBINS,
R.A. & BALDWIN, R.W. (1991). Reactivity of anti-(human gastric
carcinoma) monoclonal antibody with core-related peptides of
gastrointestinal mucin. Cancer Immunol. Immunother., 33, 80-84.
SAFI, F., KOHLER, I., ROTTINGER, E. & BEGER, H.-G. (1991). The
value of the tumour marker CA15-3 in diagnosing and monitor-
ing breast cancer. Cancer, 68, 574-582.
SHIBIER, O., HAMPTON, S.M. & MARKS, V. (1988). An immunisation
protocol which enhances the frequency of antigen-specific mono-
clonal antibody production. J. Immunol. Meth., 114, 49-52.
SKERRITT, J.H. & HILL, A.S. (1990). Monoclonal antibody sandwich
enzyme immunoassays for determination of gluten in foods. J.
Agric. Food Chem., 38, 1771-1778.
WARD, B.G., McGUCKIN, M.A., RAMM, L.E., COGLAN, M., SAND-
ERSON, B., TRIPCONY, L. & FREE, K.E. (1993). The management
of ovarian carcinoma is improved by the use ofcancer-associated
serum antigen (CASA) and CA125 assays. Cancer, 71, 430-438.
WHITEHEAD, R.H., MACRAE, F.A., ST. JOHN, J.B. & MA, J. (1985). A
colon cancer cell line (LIM1215) derived from a patient with
inherited nonpolyposis colorectal cancer. J. Nail Cancer. Inst., 74,
759-765.
WHITEHEAD, R.H., ZHANG, H.H. & HAYWARD, I.P. (1992). Charac-
terisation of a panel of colon carcinoma cell lines using tissue-
specific markers. Immunol. Cell. Biol., 70, 227-236.
XING, P.-X., TJANDRA, J.J., STACKER, S.A., TEH, J.G., THOMPSON,
C.H., MCLAUGHLIN, P.J. & MCKENZIE, I.F.C. (1989). Monoclonal
antibodies reactive with mucin expressed in breast cancer. Immun-
ol. Cell Biol., 67, 183-195.
XING, P.-X., REYNOLDS, K., TJANDRA, J.J., TANG, X.-L. & MCKEN-
ZIE, I.F.C. (1990). Synthetic peptides reactive with anti-human
milk fat globule monoclonal antibodies. Cancer Res., 50, 89-96.
XING, P.-X., PRENZOSKA, J., LAYTON, G.T., DEVINE, P.L. & MC-
KENZIE, I.F.C. (1992). Second generation monoclonal antibodies
to intestinal MUC2 peptide reactive with colon cancer. J. Natl
Cancer Inst., 84, 699-703.
YAN, P.-S., HO, S.B., ITZKOWITZ, S.H., BYRD, J.C., SIDDIQUI, B. &
KIM, Y.S. (1990). Expression of native and deglycosylated colon
cancer mucin antigens in normal and malignant epithelial tissues.
Lab. Invest., 62, 698-706.
ZEGERS, N., GERRITSE, K., DEEN, C., BOERSMA, W. & CLAASSEN,
E. (1990). An improved conjugation method for controlled cova-
lent coupling of synthetic peptides to proteins using glutaral-
dehyde in dialysis method. J. Immunol. Meth., 130, 195-200.